Montelukast
Published on 29 Apr 2024 · source: MHRA — Medicines and Healthcare products Regulatory Agency
What this means
Drug Safety Update is the MHRA bulletin for healthcare professionals: new safety information, restrictions of use and recommendations for monitoring.
Summary
Healthcare professionals prescribing montelukast should be alert to the risk of neuropsychiatric reactions in all patients including children and adolescents. Reported neuropsychiatric reactions include sleep disorders, hallucinations, anxiety and depression, as well as changes in behaviour and mood. Healthcare professionals should advise patients and their caregivers to be alert to these risks and seek medical advice as soon as possible if neuropsychiatric reactions occur.